[1]
Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R, Gynecologic Oncology Group. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003 Sep 1:21(17):3194-200
[PubMed PMID: 12860964]
[2]
Kondagunta GV, Bacik J, Donadio A, Bajorin D, Marion S, Sheinfeld J, Bosl GJ, Motzer RJ. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Sep 20:23(27):6549-55
[PubMed PMID: 16170162]
[3]
Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, Juul N, Leong CO, Calogrias D, Buraimoh A, Fatima A, Gelman RS, Ryan PD, Tung NM, De Nicolo A, Ganesan S, Miron A, Colin C, Sgroi DC, Ellisen LW, Winer EP, Garber JE. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Mar 1:28(7):1145-53. doi: 10.1200/JCO.2009.22.4725. Epub 2010 Jan 25
[PubMed PMID: 20100965]
[4]
Whitney CW, Sause W, Bundy BN, Malfetano JH, Hannigan EV, Fowler WC Jr, Clarke-Pearson DL, Liao SY. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1999 May:17(5):1339-48
[PubMed PMID: 10334517]
Level 1 (high-level) evidence
[5]
Fleming GF, Brunetto VL, Cella D, Look KY, Reid GC, Munkarah AR, Kline R, Burger RA, Goodman A, Burks RT. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004 Jun 1:22(11):2159-66
[PubMed PMID: 15169803]
[6]
Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR, Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom. Capecitabine and oxaliplatin for advanced esophagogastric cancer. The New England journal of medicine. 2008 Jan 3:358(1):36-46. doi: 10.1056/NEJMoa073149. Epub
[PubMed PMID: 18172173]
[7]
Tepper J, Krasna MJ, Niedzwiecki D, Hollis D, Reed CE, Goldberg R, Kiel K, Willett C, Sugarbaker D, Mayer R. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Mar 1:26(7):1086-92. doi: 10.1200/JCO.2007.12.9593. Epub
[PubMed PMID: 18309943]
[8]
Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J, ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. The New England journal of medicine. 2010 Apr 8:362(14):1273-81. doi: 10.1056/NEJMoa0908721. Epub
[PubMed PMID: 20375404]
[9]
Wozniak AJ, Crowley JJ, Balcerzak SP, Weiss GR, Spiridonidis CH, Baker LH, Albain KS, Kelly K, Taylor SA, Gandara DR, Livingston RB. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1998 Jul:16(7):2459-65
[PubMed PMID: 9667264]
Level 1 (high-level) evidence
[10]
Turrisi AT 3rd, Kim K, Blum R, Sause WT, Livingston RB, Komaki R, Wagner H, Aisner S, Johnson DH. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. The New England journal of medicine. 1999 Jan 28:340(4):265-71
[PubMed PMID: 9920950]
[11]
Fornasiero A, Daniele O, Ghiotto C, Piazza M, Fiore-Donati L, Calabró F, Rea F, Fiorentino MV. Chemotherapy for invasive thymoma. A 13-year experience. Cancer. 1991 Jul 1:68(1):30-3
[PubMed PMID: 2049749]
[12]
Velasquez WS, Cabanillas F, Salvador P, McLaughlin P, Fridrik M, Tucker S, Jagannath S, Hagemeister FB, Redman JR, Swan F. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood. 1988 Jan:71(1):117-22
[PubMed PMID: 3334893]
[13]
Velasquez WS, McLaughlin P, Tucker S, Hagemeister FB, Swan F, Rodriguez MA, Romaguera J, Rubenstein E, Cabanillas F. ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1994 Jun:12(6):1169-76
[PubMed PMID: 8201379]
[14]
Cushing B, Giller R, Cullen JW, Marina NM, Lauer SJ, Olson TA, Rogers PC, Colombani P, Rescorla F, Billmire DF, Vinocur CD, Hawkins EP, Davis MM, Perlman EJ, London WB, Castleberry RP, Pediatric Oncology Group 9049, Children's Cancer Group 8882. Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors: a pediatric intergroup study--Pediatric Oncology Group 9049 and Children's Cancer Group 8882. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004 Jul 1:22(13):2691-700
[PubMed PMID: 15226336]
Level 1 (high-level) evidence
[15]
Douglass EC, Reynolds M, Finegold M, Cantor AB, Glicksman A. Cisplatin, vincristine, and fluorouracil therapy for hepatoblastoma: a Pediatric Oncology Group study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1993 Jan:11(1):96-9
[PubMed PMID: 8380296]
[16]
Kim H, Kang HJ, Lee JW, Park JD, Park KD, Shin HY, Ahn HS. Irinotecan, vincristine, cisplatin, cyclophosphamide, and etoposide for refractory or relapsed medulloblastoma/PNET in pediatric patients. Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery. 2013 Oct:29(10):1851-8. doi: 10.1007/s00381-013-2163-z. Epub 2013 Jun 9
[PubMed PMID: 23748464]
[17]
Kreissman SG, Seeger RC, Matthay KK, London WB, Sposto R, Grupp SA, Haas-Kogan DA, Laquaglia MP, Yu AL, Diller L, Buxton A, Park JR, Cohn SL, Maris JM, Reynolds CP, Villablanca JG. Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. The Lancet. Oncology. 2013 Sep:14(10):999-1008. doi: 10.1016/S1470-2045(13)70309-7. Epub 2013 Jul 25
[PubMed PMID: 23890779]
Level 1 (high-level) evidence
[18]
Marina NM, Smeland S, Bielack SS, Bernstein M, Jovic G, Krailo MD, Hook JM, Arndt C, van den Berg H, Brennan B, Brichard B, Brown KLB, Butterfass-Bahloul T, Calaminus G, Daldrup-Link HE, Eriksson M, Gebhardt MC, Gelderblom H, Gerss J, Goldsby R, Goorin A, Gorlick R, Grier HE, Hale JP, Hall KS, Hardes J, Hawkins DS, Helmke K, Hogendoorn PCW, Isakoff MS, Janeway KA, Jürgens H, Kager L, Kühne T, Lau CC, Leavey PJ, Lessnick SL, Mascarenhas L, Meyers PA, Mottl H, Nathrath M, Papai Z, Randall RL, Reichardt P, Renard M, Safwat AA, Schwartz CL, Stevens MCG, Strauss SJ, Teot L, Werner M, Sydes MR, Whelan JS. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. The Lancet. Oncology. 2016 Oct:17(10):1396-1408. doi: 10.1016/S1470-2045(16)30214-5. Epub 2016 Aug 25
[PubMed PMID: 27569442]
Level 1 (high-level) evidence
[19]
Riddell IA. Cisplatin and Oxaliplatin: Our Current Understanding of Their Actions. Metal ions in life sciences. 2018 Feb 5:18():. pii: /books/9783110470734/9783110470734-007/9783110470734-007.xml. doi: 10.1515/9783110470734-007. Epub
[PubMed PMID: 29394020]
Level 3 (low-level) evidence
[20]
Aggarwal SK. A histochemical approach to the mechanism of action of cisplatin and its analogues. The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society. 1993 Jul:41(7):1053-73
[PubMed PMID: 8515048]
[21]
O'Dwyer PJ, Stevenson JP, Johnson SW. Clinical pharmacokinetics and administration of established platinum drugs. Drugs. 2000:59 Suppl 4():19-27
[PubMed PMID: 10864227]
[22]
Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA, Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. The New England journal of medicine. 2006 Jan 5:354(1):34-43
[PubMed PMID: 16394300]
[23]
Roila F, Molassiotis A, Herrstedt J, Aapro M, Gralla RJ, Bruera E, Clark-Snow RA, Dupuis LL, Einhorn LH, Feyer P, Hesketh PJ, Jordan K, Olver I, Rapoport BL, Roscoe J, Ruhlmann CH, Walsh D, Warr D, van der Wetering M, participants of the MASCC/ESMO Consensus Conference Copenhagen 2015. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Annals of oncology : official journal of the European Society for Medical Oncology. 2016 Sep:27(suppl 5):v119-v133
[PubMed PMID: 27664248]
[24]
Ener RA, Meglathery SB, Styler M. Extravasation of systemic hemato-oncological therapies. Annals of oncology : official journal of the European Society for Medical Oncology. 2004 Jun:15(6):858-62
[PubMed PMID: 15151940]
[25]
Barabas K, Milner R, Lurie D, Adin C. Cisplatin: a review of toxicities and therapeutic applications. Veterinary and comparative oncology. 2008 Mar:6(1):1-18. doi: 10.1111/j.1476-5829.2007.00142.x. Epub
[PubMed PMID: 19178659]
Level 2 (mid-level) evidence
[26]
Packer RJ, Zhou T, Holmes E, Vezina G, Gajjar A. Survival and secondary tumors in children with medulloblastoma receiving radiotherapy and adjuvant chemotherapy: results of Children's Oncology Group trial A9961. Neuro-oncology. 2013 Jan:15(1):97-103. doi: 10.1093/neuonc/nos267. Epub 2012 Oct 25
[PubMed PMID: 23099653]
[27]
Baeksgaard L, Sørensen JB. Acute tumor lysis syndrome in solid tumors--a case report and review of the literature. Cancer chemotherapy and pharmacology. 2003 Mar:51(3):187-92
[PubMed PMID: 12655435]
Level 3 (low-level) evidence
[28]
Balis FM. Pharmacokinetic drug interactions of commonly used anticancer drugs. Clinical pharmacokinetics. 1986 May-Jun:11(3):223-35
[PubMed PMID: 2426030]
[29]
Furue H. [Drug interactions with anticancer agents]. Gan to kagaku ryoho. Cancer & chemotherapy. 1985 Dec:12(12):2231-6
[PubMed PMID: 3907502]
[30]
Zheng X, Zhu Y, Zhao Y, Feng S, Zheng C. Taxanes in combination with platinum derivatives for the treatment of ovarian cancer during pregnancy: A literature review
. International journal of clinical pharmacology and therapeutics. 2017 Sep:55(9):753-760. doi: 10.5414/CP202995. Epub
[PubMed PMID: 28737125]
[31]
Brewer M, Kueck A, Runowicz CD. Chemotherapy in pregnancy. Clinical obstetrics and gynecology. 2011 Dec:54(4):602-18. doi: 10.1097/GRF.0b013e318236e9f9. Epub
[PubMed PMID: 22031250]
[33]
Otani IM, Wong J, Banerji A. Platinum Chemotherapy Hypersensitivity: Prevalence and Management. Immunology and allergy clinics of North America. 2017 Nov:37(4):663-677. doi: 10.1016/j.iac.2017.06.003. Epub 2017 Aug 19
[PubMed PMID: 28965633]
[34]
Crona DJ, Faso A, Nishijima TF, McGraw KA, Galsky MD, Milowsky MI. A Systematic Review of Strategies to Prevent Cisplatin-Induced Nephrotoxicity. The oncologist. 2017 May:22(5):609-619. doi: 10.1634/theoncologist.2016-0319. Epub 2017 Apr 24
[PubMed PMID: 28438887]
Level 1 (high-level) evidence
[35]
Karasawa T, Steyger PS. An integrated view of cisplatin-induced nephrotoxicity and ototoxicity. Toxicology letters. 2015 Sep 17:237(3):219-27. doi: 10.1016/j.toxlet.2015.06.012. Epub 2015 Jun 20
[PubMed PMID: 26101797]
Level 3 (low-level) evidence
[36]
Brock PR, Knight KR, Freyer DR, Campbell KC, Steyger PS, Blakley BW, Rassekh SR, Chang KW, Fligor BJ, Rajput K, Sullivan M, Neuwelt EA. Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012 Jul 1:30(19):2408-17. doi: 10.1200/JCO.2011.39.1110. Epub 2012 Apr 30
[PubMed PMID: 22547603]
Level 3 (low-level) evidence
[37]
Li L, Wu M, Yang JX, Wan XR, Huang HF, Pan LY, Shen K, Lang JH, Xiang Y. [Clinical analysis of hypersensitivity reaction of platinum in ovarian cancer and cervical cancer patients]. Zhonghua fu chan ke za zhi. 2016 Nov 25:51(11):825-831. doi: 10.3760/cma.j.issn.0529-567X.2016.11.005. Epub
[PubMed PMID: 27916065]
[38]
Handa S, Kuroiwa R, Miyano M, Shimizu H, Kamei D, Takei H, Sonou H, Yamamoto H, Murayama J, Sato A, Kato Y. Assessment of Injection Site Reactions for Peripheral Intravenous Oxaliplatin Infusion and Potential Remedies. Gan to kagaku ryoho. Cancer & chemotherapy. 2016 Aug:43(8):985-8
[PubMed PMID: 27539041]
[39]
Paw Cho Sing E, Robinson PD, Flank J, Holdsworth M, Thackray J, Freedman J, Gibson P, Orsey AD, Patel P, Phillips R, Portwine C, Raybin JL, Cabral S, Sung L, Dupuis LL. Classification of the acute emetogenicity of chemotherapy in pediatric patients: A clinical practice guideline. Pediatric blood & cancer. 2019 May:66(5):e27646. doi: 10.1002/pbc.27646. Epub 2019 Feb 7
[PubMed PMID: 30729654]
Level 1 (high-level) evidence
[40]
Avan A, Postma TJ, Ceresa C, Avan A, Cavaletti G, Giovannetti E, Peters GJ. Platinum-induced neurotoxicity and preventive strategies: past, present, and future. The oncologist. 2015 Apr:20(4):411-32. doi: 10.1634/theoncologist.2014-0044. Epub 2015 Mar 12
[PubMed PMID: 25765877]
[41]
Albers JW, Chaudhry V, Cavaletti G, Donehower RC. Interventions for preventing neuropathy caused by cisplatin and related compounds. The Cochrane database of systematic reviews. 2014 Mar 31:(3):CD005228. doi: 10.1002/14651858.CD005228.pub4. Epub 2014 Mar 31
[PubMed PMID: 24687190]
Level 1 (high-level) evidence
[42]
Li Y, Li Y, Li J, Pi G, Tan W. Paclitaxel- and/or cisplatin-induced ocular neurotoxicity: a case report and literature review. OncoTargets and therapy. 2014:7():1361-6. doi: 10.2147/OTT.S65774. Epub 2014 Jul 31
[PubMed PMID: 25114574]
Level 3 (low-level) evidence
[43]
Foronda C, MacWilliams B, McArthur E. Interprofessional communication in healthcare: An integrative review. Nurse education in practice. 2016 Jul:19():36-40. doi: 10.1016/j.nepr.2016.04.005. Epub 2016 May 3
[PubMed PMID: 27428690]
[44]
Yang LY, Manhas DS, Howard AF, Olson RA. Patient-reported outcome use in oncology: a systematic review of the impact on patient-clinician communication. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2018 Jan:26(1):41-60. doi: 10.1007/s00520-017-3865-7. Epub 2017 Aug 28
[PubMed PMID: 28849277]
Level 1 (high-level) evidence
[45]
Abueg KD. Interprofessional Management of Toxicities Related to Cancer Precision Medicine. Seminars in oncology nursing. 2017 Nov:33(4):376-383. doi: 10.1016/j.soncn.2017.08.005. Epub 2017 Sep 15
[PubMed PMID: 28927762]